Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature

on behalf of Precision Liver Cancer Prevention Consortium

doi:10.1002/hep.29203

Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature

on behalf of Precision Liver Cancer Prevention Consortium

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	1344-1346
Number of pages	3
Journal	Hepatology
Volume	66
Issue number	4
DOIs	https://doi.org/10.1002/hep.29203
State	Published - Oct 2017

ASJC Scopus subject areas

Hepatology

Access to Document

10.1002/hep.29203

Cite this

@article{d2416f5b04a048ef8b57a321b8a2454f,

title = "Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature",

author = "{on behalf of Precision Liver Cancer Prevention Consortium} and Atsushi Ono and Nicolas Goossens and Finn, {Richard S.} and Schmidt, {Warren N.} and Thung, {Swan N.} and Im, {Gene Y.} and Yujin Hoshida",

note = "Funding Information: Copyright VC 2017 by the American Association for the Study of Liver Diseases. View this article online at wileyonlinelibrary.com. DOI 10.1002/hep.29203 Potential conflict of interest: Dr. Finn consults for Bayer, Pfizer, Bristol-Myers Squibb, Novartis, and Eisai. Dr. Ono received grants from Bristol-Myers Squibb. Funding Information: Received January 24, 2017; accepted April 5, 2017. Supported by the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (DK099558), the European Union (ERC-2014-AdG-671231HEPCIR), the Irma T. Hirschl Trust, the US Department of Defense (W81XWH-16-1-0363, to Y.H.), and the National Institutes of Health Loan Repayment Program (to G.Y.I.).",

year = "2017",

month = oct,

doi = "10.1002/hep.29203",

language = "English (US)",

volume = "66",

pages = "1344--1346",

journal = "Hepatology",

issn = "0270-9139",

publisher = "John Wiley and Sons Ltd",

number = "4",

}

TY - JOUR

T1 - Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature

AU - on behalf of Precision Liver Cancer Prevention Consortium

AU - Ono, Atsushi

AU - Goossens, Nicolas

AU - Finn, Richard S.

AU - Schmidt, Warren N.

AU - Thung, Swan N.

AU - Im, Gene Y.

AU - Hoshida, Yujin

N1 - Funding Information: Copyright VC 2017 by the American Association for the Study of Liver Diseases. View this article online at wileyonlinelibrary.com. DOI 10.1002/hep.29203 Potential conflict of interest: Dr. Finn consults for Bayer, Pfizer, Bristol-Myers Squibb, Novartis, and Eisai. Dr. Ono received grants from Bristol-Myers Squibb. Funding Information: Received January 24, 2017; accepted April 5, 2017. Supported by the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (DK099558), the European Union (ERC-2014-AdG-671231HEPCIR), the Irma T. Hirschl Trust, the US Department of Defense (W81XWH-16-1-0363, to Y.H.), and the National Institutes of Health Loan Repayment Program (to G.Y.I.).

PY - 2017/10

Y1 - 2017/10

UR - http://www.scopus.com/inward/record.url?scp=85028297319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028297319&partnerID=8YFLogxK

U2 - 10.1002/hep.29203

DO - 10.1002/hep.29203

M3 - Comment/debate

C2 - 28390144

AN - SCOPUS:85028297319

SN - 0270-9139

VL - 66

SP - 1344

EP - 1346

JO - Hepatology

JF - Hepatology

IS - 4

ER -

Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this